Observational studyEpilepsia2026
Maternal and umbilical cord plasma concentrations of antiseizure medications: Results from the observational MONEAD study.
Observational study in Epilepsia, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
objectiveUnanticipated changes in antiseizure medication (ASM) exposure can lead to subtherapeutic or toxic medication concentrations in the mother and unnecessary drug exposure for the fetus. The objectives of this study were to characterize ASM concentrations in mother's and cord blood at delivery in women with epilepsy (PWWE).
methodsThe analysis included PWWE (aged 14-45 years) from the Maternal Outcomes and Neurodevelopmental Effects of Antiepileptic Drugs study who were on ASM monotherapy or polytherapy at delivery. Women with an intelligence quotient < 70, major medical illness, substance use, and poor treatment adherence were excluded. Blood samples were collected from the mother and umbilical cord on the day of delivery. The ratio of umbilical cord to maternal plasma concentration at birth was used as a measure of fetal in utero exposure. Pearson correlation coefficients were calculated to determine the degree of correlation between ASM maternal and cord plasma concentrations. A p-value of <.05 was deemed to be significant.
resultsData from 207 infants included eight pairs of twins (104 females and 103 males) born to 199 women (140 on monotherapy and 59 on polytherapy), yielding 305 paired maternal and umbilical cord ASM concentrations. Significant correlation was observed between umbilical cord and maternal plasma concentrations for total and unbound carbamazepine, total and unbound carbamazepine-10,11-epoxide, gabapentin, lamotrigine, levetiracetam, total and unbound oxcarbazepine, and zonisamide. The mean ratios (SD) of umbilical cord plasma concentration to maternal plasma concentration were as follows: carbamazepine = .84 (.18), unbound carbamazepine = 1.15 (.47), carbamazepine-10,11-epoxide = .87 (.18), unbound carbamazepine epoxide = 1.17 (.36), gabapentin = 1.56 (.28), lacosamide = .96 (.29), levetiracetam = 1.1 (.53), lamotrigine = .92 (.26), oxcarbazepine = 1.01 (.22), unbound oxcarbazepine = 1.1 (.46), topiramate = .98 (.38), valproic acid = 1.03 (.85), unbound valproic acid = .73 (.74), and zonisamide = .93 (.12). SIGNIFICANCE: Umbilical cord to maternal ASM concentration ratios were close to 1.0, indicating placental passage of ASMs. Gabapentin had the highest ratio, suggesting possible accumulation of drug. Additional studies are needed for infrequently prescribed ASMs.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.